Results 81 to 90 of about 103,599 (300)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Additional file 1 of ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers

open access: yes, 2022
Additional file 1: Supplementary Information. Figure S1. Supplemental ARID1A knockdown differential H3.3 data. Figure S2. H3.3 knockdown functional analysis. Figure S3. Effects of CHD4 loss on H3.3 chromatin and comparison to ARID1A.
Scott B. Rothbart (1616755)   +10 more
core   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

open access: yesMolecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi   +6 more
wiley   +1 more source

Erythrina foliage as an alternative feed for growing goats in Lao PDR [PDF]

open access: yes, 2012
Foliages from some tropical plants and from different species of the legume Erythrina were examined in five studies assessing the characteristics of these foliages as feed for goats.
Kongmanila, Daovy
core   +1 more source

Safety and efficacy of APSA PHYTAFEED® (6‐phytase) as a feed additive for laying hens and other laying birds

open access: yesEFSA Journal, 2020
Following a request from the European Commission, the EFSA Panel on Additives and products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of APSA PHYTAFEED® 20,000 GR/L (6‐phytase) as a ...
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)   +20 more
doaj   +1 more source

Enhancers of eight Gossypium species.

open access: yes, 2021
Enhancers of eight Gossypium ...
Jianying Li (9426689)
core   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

open access: yesMolecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad   +2 more
wiley   +1 more source

The summary of the overlap between the predicted enhancers and the FANTOM5 enhancers.

open access: yes, 2016
The summary of the overlap between the predicted enhancers and the FANTOM5 enhancers.
Yang Dai (36730)   +2 more
core   +1 more source

Validation using PacBio SVs and disease enhancers.

open access: yes, 2020
a) Cumulative distribution function for LoF-tolerant scores for disease enhancers (red), all tested enhancers (grey), PacBio deleted enhancers (blue). KS-test P-values are between disease enhancers vs. all tested and PacBio enhancers vs. all tested.
Ekta Khurana (386863)   +2 more
core   +1 more source

NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis

open access: yesMolecular Oncology, EarlyView.
Loss of NAPRT promotes lung tumor initiation and growth through a noncanonical mechanism, independent of its role in NAD+ biosynthesis. Mechanistically, NAPRT depletion activates the mTORC2‐driven AKT/β‐catenin signaling axis to enhance clonogenic and invasive phenotypes. Furthermore, lung‐specific Naprt deletion significantly increases tumor burden in
Myung Joon Oh   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy